Sensei Biotherapeutics, Inc. (SNSE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Sensei Biotherapeutics, Inc. (SNSE) is up 50.8% since the beginning of the year. At $16 per share, SNSE is trading 56.2% below its 52-week high of $37. Investors who bought $1,000 worth of SNSE shares 5 years ago would now be looking at an investment worth $64.

Sensei Biotherapeutics, Inc. (SNSE) has returned 50.84% so far this year and 138.02% over the past 12 months.

Based on dividend-adjusted daily data since Feb 4, 2021, SNSE's average daily return is +0.02%, while the average monthly return is -1.75%.

Historically, 29% of months were positive and 71% were negative. The best month was Feb 2026 with a return of +221.1%, while the worst month was Mar 2022 at -36.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.

On a daily basis, SNSE closed higher 43% of trading days. The best single day was Feb 18, 2026 with a return of +187.5%, while the worst single day was May 24, 2024 at -45.5%.

Sensei Biotherapeutics, Inc. has an annualized alpha of -9.62%, beta of 1.07, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since February 05, 2021.

• This stock participated in 90.65% of S&P 500 Index downside but only -88.31% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SNSE ranks 80 for risk / return — better than 80% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Sensei Biotherapeutics, Inc. (SNSE) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Sensei Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Sensei Biotherapeutics, Inc. was 98.73%, occurring on Apr 4, 2025. The portfolio has not yet recovered.

The current Sensei Biotherapeutics, Inc. drawdown is 96.46%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Sensei Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Sensei Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.